Press release - 18/10/2023 SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
Press release - 17/10/2023 BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-und-yumab-verkuenden-partnerschaft-fuer-entwicklung-innovativer-safety-engager-r-plattform
Press release - 04/10/2023 Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®). https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
Press release - 21/09/2023 Mutation-specific peptide vaccine against midline gliomas used in patients for the first time Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time
Press release - 28/08/2023 Innovative computational approach helps design proteins for cancer treatment The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment
DNA nanotechnology - 25/08/2023 Artificial cytoskeleton made of DNA for synthetic cells The physicists Prof. Dr. Kerstin Göpfrich and Prof. Dr. Laura Na Liu want to understand life from the bottom up. They intend to do this by constructing an artificial cell. However, rather than natural protein building blocks, they are using 3D-DNA structures as construction material. The first step involved creating an artificial cell skeleton that dynamically assembles and disassembles like the biological model and can transport vesicles.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-cytoskeleton-made-dna-synthetic-cells
Press release - 02/08/2023 Freiburg research team casts light on signal-dependent formation of mitochondria Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria. https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
Press release - 20/07/2023 Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention
Press release - 12/07/2023 Mast cells as a sensor: Enigmatic immune cells help to avoid harmful allergens The function of mast cells, which are part of the immune system, is still a mystery. Scientists at the German Cancer Research Center (DKFZ) have now shown in mice: mast cells function as a sensor that signals the animals to avoid antigens, including harmful allergens, and thereby protect themselves from health-threatening inflammatory reactions. The findings were published in the journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mastzellen-als-sensor-raetselhafte-immunzellen-helfen-schaedliche-allergene-zu-vermeiden
Press release - 23/06/2023 The molecular control centre of our protein factories Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
Predicting the success of cancer treatment - 20/06/2023 Focusing on gut microbiome for CAR T-cell therapy Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy
Press release - 24/05/2023 Epigenetic profiling identifies potential COPD treatment targets Impaired function of lung fibroblast is considered causative for symptoms of the incurable lung disease COPD (Chronic Obstructive Pulmonary Disease). Using high-resolution epigenetic profiling, German and British scientists have now identified potential targets for COPD treatment. The team detected early epigenetic changes in the genome of COPD fibroblasts, providing new insights into the disease pathogenesis and potential therapeutic avenues.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-profiling-identifies-potential-copd-treatment-targets
Press release - 22/05/2023 Prevention of pandemics Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-pandemics
Press release - 16/05/2023 Mast cells have an important impact on the development of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
Press release - 09/05/2023 New strategy for clinically relevant protein sequencing Proteins have characteristic amino acid sequences, the analysis of which is fundamental for research and medicine. These can be decoded; however, so-called protein sequencing is expensive and time-consuming. A large-scale research project led by Prof. Dr. Jan Behrends from the Institute of Physiology at the University of Freiburg now aims to establish a new technology for protein sequencing using nanopores, which will be rapid and cost-effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-strategy-clinically-relevant-protein-sequencing
Press release - 24/04/2023 Hidden RNA repair mechanism discovered in humans Konstanz researchers discover the function of a previously unexplored protein: In three characteristic steps, "C12orf29" links the ends of RNA strands. Proteins that perform this kind of RNA ligation were previously unknown in humans. The results of the study suggest that it is important for RNA repair during cellular stress.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hidden-rna-repair-mechanism-discovered-humans
Press release - 24/01/2023 Genome Editing Procedures Optimised Heidelberg scientists succeed in boosting the efficiency of CRISPR/Cas9 and related methods and modifying initially inaccessible DNA sequences.https://www.gesundheitsindustrie-bw.de/en/article/press-release/verfahren-der-genom-editierung-optimiert
Press release - 17/01/2023 Sugar-based inhibitors disarm the pathogen Pseudomonas aeruginosa The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zuckerbasierte-inhibitoren-entwaffnen-den-krankheitserreger-pseudomonas-aeruginosa
Press release - 05/01/2023 Formation of pores in mitochondrial membrane elucidated Mitochondria are considered to be the power plants of cells and are essential for human metabolism. Dysfunction in 40 percent of mitochondrial proteins are associated with human diseases, which is why mitochondria also play an important role in medical research. A previously unexplained process in the complex mitochondria was the formation of their barrel pores.https://www.gesundheitsindustrie-bw.de/en/article/press-release/formation-pores-mitochondrial-membrane-elucidated
Press release - 20/12/2022 Enzyme inhibition promotes bone formation and curbs the development of bone metastases In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-inhibition-promotes-bone-formation-and-curbs-development-bone-metastases
Press release - 20/12/2022 New approach prevents rejection of transplanted organs Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevents-rejection-transplanted-organs
Neurodegenerative diseases - 12/12/2022 Blood-based biomarkers allow the early prediction of Alzheimer's risks Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
Press release - 09/12/2022 Epigenetic emergency switch improves defense against infections During infections, the hematopoietic system switches from normal to emergency mode. This improves the defense against the pathogens. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found an epigenetic switch in blood stem cells and progenitor cells of mice that can trigger the switch from one mode to the other.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-emergency-switch-improves-defense-against-infections
Press release - 24/11/2022 SARS-CoV-2 detection in 30 minutes using gene scissors Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA. https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-nachweis-30-minuten-mit-der-genschere
Press release - 17/11/2022 New target for Alzheimer's therapies found DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-target-alzheimers-therapies-found
Press release - 04/11/2022 How do our brain cells age? The health of nerve cells is closely linked to the auxiliary cells that surround them, the so-called glial cells. It still remains largely unknown what role glial cells play in age-related diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-altern-die-zellen-unserem-gehirn
Press release - 02/11/2022 How Cells Find the Right Partners During the growth and development of living organisms, different types of cells must come into contact with each other in order to form tissues and organs together. A small team working with Prof. Dr. Anne Classen of the Excellence Cluster CIBSS of the University of Freiburg has discovered that complex changes in form, or morphogenesis, during development are driven exclusively via the affinity of cells to each other.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-cells-find-right-partners
Press release - 02/11/2022 The guardian of the (epi-)genome Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
Viral cancer therapy - 26/10/2022 Therapeutic viruses against tumours and metastases Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
Press release - 25/10/2022 Three ERC Synergy Grants For Universität Heidelberg Scientists Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-erc-synergy-grants-universitaet-heidelberg-scientists
Press release - 24/10/2022 How tumors suppress the development of metastases Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 19/10/2022 Molecular structure of one of the most important receptors in the immune system unraveled Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
Press release - 28/09/2022 First successful trial for early detection of HPV-related cancer of the pharynx Screening trials for the early detection of rare diseases often fail due to insufficient predictive power of the results. For the rare HPV-related cancer of the pharynx, scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) now relied on the combined detection of antibodies against two different viral proteins in a proof-of concept trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erste-erfolgreiche-studie-zur-frueherkennung-von-hpv-bedingtem-krebs-im-rachenraum
Hummingbird Diagnostics GmbH - 22/09/2022 The great potential of blood-based microRNA analyses "The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.https://www.gesundheitsindustrie-bw.de/en/article/news/great-potential-blood-based-microrna-analyses
Press release - 21/09/2022 ERC funding: How to deliver gene therapies to a specific target site? With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
Press release - 09/09/2022 Breaking down proteins: How starving cancer cells switch food sources Cancer cells often grow in environments that are low in nutrients, and they cope with this challenge by switching their metabolism to using proteins as alternative "food". Building on genetic screens, an international team of scientists could identify the protein LYSET as part of a pathway that allows cancer cells to make this switch. Their findings are now published in the journal Science.https://www.gesundheitsindustrie-bw.de/en/article/press-release/neu-identifiziertes-protein-ermoeglicht-krebszellen-auf-alternative-nahrungsquellen-auszuweichen
Press release - 31/08/2022 Using nanopores to detect epigenetic changes faster Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-nanopores-detect-epigenetic-changes-faster
Press release - 18/08/2022 When smooth muscle cells lack strength University of Tübingen team discovers how malformations of the blood vessels can occur in mice – yielding information with possible ramifications for retinal disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/when-smooth-muscle-cells-lack-strength
Press release - 29/06/2022 RNA modifications in mitochondria promote invasive spread of cancer Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
Press release - 21/06/2022 Another step towards synthetic cells Scientists from the 2. Physics Institute at the University of Stuttgart and the Max Planck Institute for Medical Research were now able to take the next step towards synthetic cells: They introduced functional DNA-based cytoskeletons into cell-sized compartments and showed functionality. The results were recently published in Nature Chemistry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-synthetic-cells
Press release - 20/06/2022 Protein changes in the liquor indicate inflammatory processes in the brain Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/protein-changes-liquor-indicate-inflammatory-processes-brain
Press release - 03/06/2022 Deep Learning helps improve gene therapies and antiviral drugs The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
Press release - 12/05/2022 New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
Press release - 28/04/2022 Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
Press release - 25/04/2022 Reprogrammed macrophages promote spread of breast cancer Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
Peptide-based COVID-19 vaccine - 21/04/2022 CoVac-1: T-cell activator against COVID-19 Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
Press release - 13/04/2022 Emmy Noether funding for research into drug resistance of blood cancer The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/emmy-noether-funding-research-drug-resistance-blood-cancer
Press release - 29/03/2022 Biocopy presents "ValidaTe" – A novel ultra-fast screening technology ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology